| Literature DB >> 2177039 |
V Vuddhakul1, G T Mai, J G McCormack, W K Seow, Y H Thong.
Abstract
Itraconazole and fluconazole are triazole compounds recently licensed for the therapy of systemic fungal infections. At 10 micrograms/ml concentrations, itraconazole was found to suppress neutrophil chemotaxis, random movement, deoxyglucose uptake and hexose-monophosphate shunt activity to the same extent as ketoconazole, an older generation azole antifungal. Itraconazole was also found to suppress mitogen-induced lymphocyte transformation to the same extent as ketoconazole at concentrations as low as 1 microgram/ml. By contrast, significant inhibition of both neutrophil and lymphocyte functions was not observed with fluconazole at concentrations as high as 50 micrograms/ml. These results suggest that fluconazole may be less immunotoxic than itraconazole, and may be more suitable for use in immunocompromised patients.Entities:
Mesh:
Substances:
Year: 1990 PMID: 2177039 DOI: 10.1016/0192-0561(90)90101-r
Source DB: PubMed Journal: Int J Immunopharmacol ISSN: 0192-0561